Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 565 results for pregnancy

  1. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  2. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  3. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  4. LiMAx system for assessing the functional capacity of the liver (MIB168)

    NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .

  5. AlignRT in breast cancer radiotherapy (MIB157)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .

  6. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  7. Contraception: LARC for people using emergency contraception (IND149)

    This indicator covers the percentage of women, on the register, prescribed emergency hormonal contraception 1 or more times in the preceding 12 months by the contractor who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM115

  8. Contraception: LARC for people on oral or patch contraceptives (IND148)

    This indicator covers the percentage of women, on the register, prescribed an oral or patch contraceptive method in the preceding 12 months who have also received information from the contractor about long acting reversible methods of contraception in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM114

  9. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

  10. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  11. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .

  12. Thora-3Di for assessing asthma in children (MIB122)

    NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .

  13. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .

  14. CytoSorb therapy for sepsis (MIB87)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .

  15. Transition between inpatient mental health settings and community or care home settings (NG53)

    This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.